Fingerprint
Dive into the research topics of 'Phase I trial of the Pan-PI3K inhibitor pilaralisib (SAR245408/XL147) in patients with chronic lymphocytic leukemia (CLL) or relapsed/refractory lymphoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically